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Abstract Alpha-1-adrenergic receptors (α1-ARs) regulate
coronary arterial blood flow by binding catecholamines,
norepinephrine (NE), and epinephrine (EPI), causing
vasoconstriction when the endothelium is disrupted.
Among the three α1-AR subtypes (α1A, α1B, and α1D),
the α1D subtype predominates in human epicardial
coronary arteries and is functional in human coronary
smooth muscle cells (SMCs). However, the presence or
function of α1-ARs on human coronary endothelial cells
(ECs) is unknown. Here we tested the hypothesis that
human epicardial coronary ECs express functional α1-ARs.
Cultured human epicardial coronary artery ECs were
studied using quantitative real-time reverse transcription
polymerase chain reaction, radioligand binding, immuno-
blot, and 3H-thymidine incorporation. The α1B-subtype
messenger ribonucleic acid (mRNA) was predominant in
cultured human epicardial coronary ECs (90–95% of total
α1-AR mRNA), and total α1-AR binding density in ECs
was twice that in coronary SMCs. Functionally, NE and
EPI through the α1B subtype activated extracellular signal-
regulated kinase (ERK) in ECs, stimulated phosphorylation
of EC endothelial nitric oxide synthase (eNOS), and
increased deoxyribonucleic acid (DNA) synthesis. These
results are the first to demonstrate α1-ARs on human
coronary ECs and indicate that the α1B subtype is
predominant. Our findings provide another potential mech-
anism for adverse cardiac effects of drug antagonists that
nonselectively inhibit all three α1-AR subtypes.
Keywords Human heart . Endothelial cell . Coronary
artery . Alpha-1-adrenergic receptor . Alpha-adrenergic
antagonists
Introduction
Alpha-1-adrenergic receptors (α1-ARs) regulate coronary
artery blood flow in response to the catecholamines
norepinephrine (NE) and epinephrine (EPI). α1-ARs on
vascular smooth muscle cells (SMCs) mediate contraction.
Interestingly, however, α1-AR stimulation causes minimal
constriction of normal coronary arteries, but markedly
constricts coronary arteries with disrupted endothelium
(Baumgart et al. 1999; Heusch et al. 2000). A likely
mechanism is loss of endothelial nitric oxide synthase
(eNOS) activation and vasodilator NO when endothelial
cells (ECs) are lost (Zembowicz et al. 1991; Jones et al.
1993). However, nothing is known about α1-ARs on
human coronary endothelial cells (ECs).
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α1-ARs exist as three molecular subtypes, α1A, α1B, and
α1D. All three subtypes are activated by NE and EPI, but
differ in amino acid sequence, tissue expression, and signaling
(Graham et al. 1996). Little is known about α1-AR subtypes
in ECs of any vascular bed or species. A few earlier studies
suggested that the α1D subtype was present in ECs from
different vascular beds in animals (Filippi et al. 2001; de
Andrade et al. 2006; Mendez et al. 2006) and in human
umbilical vein ECs (Vinci et al. 2007). However, α1-ARs in
epicardial coronary artery ECs have never been studied, in
animals or humans.
Recently, we showed that the α1D is the predominant α1-
AR subtype in human epicardial coronary arteries, which have
low levels of the α1B subtype (25% or less of total α1-ARs)
and little or noα1A (Jensen et al. 2009b). The α1D subtype is
also expressed and functional on human coronary SMCs
(Jensen et al. 2009b) and causes constriction of mouse
coronary arteries (Turnbull et al. 2003; Chalothorn et al.
2003). In striking contrast with coronary arteries, the human
and mouse myocardium and cardiac myocytes express near-
equal levels of the α1A and α1B subtypes, with little or no
α1D (Jensen et al. 2009a; O’Connell et al. 2003).
Which α1-subtypes are present on human coronary ECs is
potentially very important clinically. Subtype-nonselective
α1-adrenergic antagonists, such as doxazosin and prazosin,
are in widespread clinical use, especially to treat prostate
disease inmen and hypertension. However, large clinical trials
detected adverse cardiac effects of nonselectiveα1-antagonists
(ALLHAT CRG 2000; Cohn 1993). We suggested recently
that adaptive signaling through the α1A and α1B subtypes in
myocardium and myocytes might explain these adverse
effects in part (Jensen et al. 2009a; O’Connell et al. 2006).
Furthermore, inhibiting an α1-AR subtype in epicardial
coronary ECs might disturb endothelial-dependent vasodila-
tion. Thus, the presence of α1-ARs on epicardial coronary
ECs would suggest another possible explanation for cardiac
side effects of nonselective alpha-blockers. Here, we tested
the hypothesis that human epicardial coronary ECs express
functional α1-ARs.
Materials and methods
Human epicardial coronary artery EC culture
Clonetics normal human coronary artery ECs were from
Lonza (Walkersville, MD, #CC2585, Lots 7F3649, 7F3667,
and 7F4280). All cells were cultured in Clonetics EGM-2
medium [including human recombinant epidermal growth
factor, fibroblast growth factor, insulin-like growth factor-1,
vascular endothelial growth factor, heparin, and 2% fetal
bovine serum (FBS)] and were used between passages 3
and 10, at 80–100% confluence.
Primary human coronary artery EC cultures came from
heart transplants at the University of California, San Francisco
(UCSF), with the approval of the UCSF Committee for
Human Research and with full informed consent. The heart
was perfused with cold cardioplegia in situ and explanted
immediately into ice-cold physiologic solution. Epicardial
coronary arteries were dissected, cleaned rapidly of fat,
transported in ice-cold physiologic solution, then opened
longitudinally and digested 20 min in Hanks buffer with
collagenase type II (1 mg/ml, Worthington). The endothelium
was removed with gentle scraping; the vessel was washed
three times; collagenase was inactivated by EGM-2; and the
cellular fraction was centrifuged at 1,200 rpm for 5 min. Cells
were plated and grown in EGM-2 as with Lonza ECs and
assayed at ~80% confluence.
Human coronary artery SMC culture
Clonetics normal human coronary artery SMCs from Lonza
(#CC2583) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS for 3–11 passages and
harvested at ~70% confluence.
Quantitative real-time reverse transcription (RT) PCR
(qPCR)
Cultured coronary artery ECs from one T75 flask were
washed with phosphate buffered saline (PBS), and ribonu-
cleic acid (RNA) was extracted, purified (Qiagen RNeasy
Mini Kit), and treated with DNase (Turbo DNAfree,
Ambion). The approach was validated previously (Jensen
et al. 2009a).
RT reactions used 1 μg RNA, SuperScript III Reverse
Transcriptase (Invitrogen), random hexamers (Invitrogen),
and oligo-dT (Roche). qPCR was done in triplicate in an
ABI PRISM 7900HT Sequence Detection System (SDS)
with 5% of the RT product, primers at 125 nM, and SYBR
Green Master (Roche) with ROX reference dye. Data were
analyzed with SDS software version 2.3 (Applied Bio-
systems).
Primers were:
& β-actin forward (F) ATTGGCAATGAGCGGTTC, β-
actin reverse (R) GGATGCCACAGGACTCCAT;
& TATA-binding protein (TBP) F GGGCACCACTC
CACTGTATC, TBP R CTCATGATTACCGCAG
CAAA;
& α1A F GGCTCCTTCTACCTGCCTCT, α1A R
AGGGCTTGAAATCAGGGAAG;
& α1B F CCTGAGGATCCATTCCAAGA, α1B R
GGTTGAGGCAGCTGTTGAAG;
& α1D F TCTGCTGGTTCCCTTTCTTC, α1D R
CACGCAGCTGTTGAAGTAGC;
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& β3-AR F ATGCCAATTCTGCCTTCAAC, β3-AR R
CTTGGGGAGTTTCTTAGGCC;
& Smooth muscle myosin heavy chain (sm-MHC) F
GGAGGCCCTAAAGACAGAGC, sm-MHC R
TCTTCAGCACCGTCACCTC; and
& Platelet/endothelial cell adhesion molecule-1 (PECAM-
1) F AGGTTCTGAGGGTGAAGGTG, PECAM-1 R
ACAGCACATTGCAGCACAA
Relative quantitation of PCR products used the ΔΔCT
method, with normalization to two reference genes for
improved accuracy, where arbitrary units (AU) were
2ΔΔCT  1; 000 (CT = cycles to threshold, and ΔΔCT =
[(mean target gene CT)-(mean CT of β-actin+TBP)].
Radioligand binding
ECs or SMCs (12×100 mm dishes or 16×T75 flasks) were
rinsed, scraped directly into binding buffer (5 mM Tris–HCl,
pH 7.4, 5 mM EDTA), and sonicated. α1-AR saturation
binding used 85–95 μg cell protein in 1 ml/tube with six
concentrations (0.04–1.2 nM) in triplicate of 3H-prazosin
(Perkin-Elmer); phentolamine (10 μM, Sigma #P7561)
defined nonspecific binding. All incubations were 60 min
at 30°C. Prism 4.0a (GraphPad Software, San Diego, CA)
analyzed binding data.
Pharmacology and immunoblots
For experiments, EC cultures in 35 mm culture dishes
(Falcon) were serum-starved for 2 h in DMEMwith 5 mg/ml
bovine serum albumin (BSA), then were pre-incubated for
15 min without or with α1-AR-antagonists including
BMY-7378 (8-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-
8-azaspiro[4.5]decane-7,9-dione dihydrochloride, Sigma
#B134) or prazosin (Sigma #P7791). The nonselective β-
AR antagonist L-propranolol (Sigma #P8688) was also
present throughout. Agonists or vehicle (100 μM ascorbic
acid) were then added including L-NE-bitartrate (Sigma
#N5785), L-EPI-bitartrate (Sigma #E4375), A61603 (N-
[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,
8-tetrahydronaphthalen-1-yl]methanesulfonamide hydrobro-
mide, Tocris #1052, Ellisville, MO), or UK-14,304
[5-bromo-N- (2-imidazolin-2-yl)-6-quinoxalinamine, 5-
bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine,
Sigma #U104].
After agonist treatment, homogenates were made in
radioimmunoprecipitation assay (RIPA) buffer with prote-
ase and phosphatase inhibitors. Total cell lysates were used
in immunoblots with antibodies for total-ERK1/2 (Cell
Signaling rabbit pAb #9102), phospho-ERK1/2 (Cell
Signaling rabbit mAb Thr202/Tyr204 #4370), total-eNOS
(BD Transduction Laboratories #610296), and phospho-
eNOS (Cell Signaling Ser-1177 #9571; BD Transduction
Ser-633 #612665). Signals from enhanced chemilumines-
cence detection were quantified with a Bio-Rad ChemiDoc
Molecular Imager (Hercules, CA).
Antibodies for cell phenotyping were PECAM-1 (R&D
Systems #BBA7), smooth muscle actin (Zymed #08-0106),
and sm-MHC (Biomedical Technologies #BT-562, Stoughton,
MA).
3H-Thymidine incorporation
DNA synthesis was estimated by measuring incorporation
of 3H-thymidine. ECs at 80–90% confluence in 24-well
plates in EGM-2 were serum-starved and pre-incubated
for 4 h in DMEM with BSA (5 mg/ml, Sigma #A7030)
and L-propranolol 1 μM, without or with prazosin 0.2 μM.
Cells were then incubated in the same medium with 3H-
thymidine, without or with NE or EPI. After 24 h, cells
were extracted with 10% trichloroacetic acid for 12 h,
washed, dissolved in 1% SDS for 1 h, and counted in mini-
vials with 5 ml Opti-fluor (Perkin-Elmer).
Data analysis
Results are mean ± SEM. Significant differences (p<0.05)
were tested using Student’s unpaired t-test for two groups,
and analysis of variance (ANOVA) and Tukey’s multiple
comparison for more than two groups. Concentration–
response curves were fit with Prism 4.0a.
Results
Validation of human epicardial coronary EC cultures
Human coronary ECs from Lonza were from two females
(ages 56 and 57) and one male (age 21). These ECs all
expressed high levels of PECAM-1 mRNA and no sm-
MHC, as expected (data not shown). Our primary cultures
of human epicardial coronary ECs were from one male
without coronary artery disease (age 46) and were validated
by positive immunoblot for PECAM-1 and by negative
immunoblot for smooth muscle actin and sm-MHC (data
not shown).
α1B-AR subtype mRNA predominates in human coronary
ECs (Fig. 1)
We quantified α1-AR subtype mRNAs using qPCR
with primers validated previously that span the single
intron in each α1-AR subtype gene to eliminate
artifacts from genomic DNA contamination (Jensen et
al. 2009a). In the Lonza ECs, 92% of total α1-AR mRNA
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was α1B, with the remainder small amounts of α1D, and
little or no α1A (N=4 independent cultures from three
subjects, Fig. 1a). There was no detectable β3-AR mRNA
(data not shown). In our primary human epicardial ECs,
90% of total α1-AR mRNA was α1B (N=2 cultures from
one subject).
α1-AR binding is higher in ECs than in SMCs (Fig. 1)
To test α1-AR protein levels, we used saturation radio-
ligand binding with 3H-prazosin. We could not use
immunohistochemistry or immunoblot, because there are
no antibodies specific for α1-ARs, among 10 antibodies
that we tested (Jensen et al. 2009c), or three antibodies
tested by others (Pradidarcheep et al. 2009).
Saturation binding identified 34 fmol/mg protein of total
α1-ARs in coronary ECs, with a Kd 0.07 nM, and specific
binding 90% of total at the 3H-prazosin Kd (Fig. 1b). For
comparison, in parallel experiments, we found that Lonza
human coronary SMCs contained 17 fmol/mg protein of
total α1-ARs. We did not perform competition radioligand
binding on ECs given the marked predominance of α1B
mRNA in our qPCR assays.
α1B subtype activates ERK in coronary artery ECs (Fig. 2)
To test for functional α1-ARs in human coronary ECs and
to determine the α1-AR subtype at the protein level, we
used immunoblot to quantify dual Thr202/Tyr204 phos-
phorylation (activation) of ERK. ERK is a key target for
α1-ARs in cardiac myocytes (Huang et al. 2007) and is a
key element of important signaling pathways in ECs that
promote angiogenesis (Chung et al. 2008), and EC
migration, survival, and proliferation (Lian et al. 2001;
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Fig. 1 α1-ARs in human epicardial coronary ECs. α1-AR subtype
mRNAs were quantified by qPCR in Lonza cultured ECs (N=4,
a), and total α1-ARs were measured by saturation radioligand
binding (b)
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Fig. 2 The α1B-AR subtype activates ERK in coronary ECs.
Cultured ECs were treated for 15 min with the drugs indicated, and
total and phosphorylated ERK were quantified by immunoblot. The
nonselective β-AR antagonist propranolol (1 μM) was present
throughout in all groups. a Representative blot with NE, EPI, and
the α1A-selective agonist A61603. b ERK activation by NE (mean
1 μM, range 0.2–2 μM) is inhibited by the nonselective α1-antagonist
prazosin (1 μM, N=6–10). c The α1D-selective antagonist, BMY-
7378, inhibited NE (1 μM)-stimulated phospho-ERK with a log IC50
of −6.5 (N=5). This value is much closer to the known low-affinity
BMY-7378 site (log IC50 -5.6) than the high-affinity site (−10.9)
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Mavria et al. 2006; Nakagami et al. 2001; Secchiero et al.
2003).
Human coronary ECs from Lonza were treated 15 min
with the non-subtype-selective natural α1-AR agonists NE
and EPI, and the α1A-selective agonist, A61603, in the
presence of propranolol, a β-AR antagonist. NE increased
phospho-ERK by 2.2-fold, and the general α1-AR antag-
onist prazosin reduced this activation by 70% (p=0.01, N=
6–10 cultures; Fig. 2a–b). The α1A agonist A61603 did not
activate ERK (N=3; Fig. 2a). The subtype-nonselective α2-
AR agonist UK-14,304 (10 μM) increased phospho-ERK
by only 1.11-fold.
These data indicated that an α1-AR subtype activated
ERK in human coronary ECs and that the subtype was not
the α1A, because A61603 was inactive. To determine
whether the α1B and/or α1D activated ERK, we used an
α1D-selective agent, because there are no reliable α1B-
selective agonists or antagonists. We quantified ERK
phosphorylation after stimulation with NE (1 μM) for
15 min, in the presence of propranolol to block β-ARs, and
varying concentrations of BMY-7378 (1 nM–1 μM), the
α1D-selective antagonist.
Previously, we found that BMY-7378 competed for 3H-
prazosin binding to human epicardial coronary artery α-ARs
at two receptor sites, one with high affinity (log IC50 -10.9,
the α1D) and the other with low affinity (log IC50 -5.6, the
α1A or α1B; Jensen et al. 2009b). In the present experiments,
BMY-7378 inhibited NE-stimulated phospho-ERK with a log
IC50 -6.5, very close to the low affinity log IC50 (N=5
cultures; Fig. 2c). These data showed that NE-induced ERK
phosphorylation in human coronary ECs is not mediated by
the α1D, because BMY-7378 inhibited with low affinity, and
therefore is mediated by the α1B.
In summary, human coronary artery ECs expressed
functional α1B-ARs that activated the important intracel-
lular mediator ERK in response to stimulation by modest
concentrations of adrenergic agonists.
α1-ARs activate eNOS in ECs (Fig. 3)
eNOS is a key regulator of EC function, including
vasorelaxation and angiogenesis (Zembowicz et al. 1991;
Murohara et al. 1998), and is activated by α1-ARs in some
systems (Hodges et al. 2005). To test whether α1-ARs in
human epicardial coronary ECs signal through eNOS, we
treated with α1-AR agonists and measured increased
phosphorylation of eNOS at two common activation sites
(Ser-1177 and Ser-633).
NE (1 μM) and EPI (2 μM) in the presence of
propranolol each transiently increased phosphorylation
of eNOS at Ser-1177, with a maximum at 30 min
(Fig. 3a). In three independent cultures, α1-AR stimulation
increased phopsho-eNOS (Ser-1177) by 1.85-fold over
vehicle (p=0.01) but did not change phosphorylation at
Ser-633. The α1A-selective agonist, A61603, did not
increase eNOS phosphorylation at either Ser-1177 or Ser-
633 (data not shown).
These data indicated that an α1-AR, most likely the
α1B, activated eNOS at Ser-1177 in human coronary artery
ECs. However, we were unable to detect NO production in
our cultures using the fluorophore DAF-2 or the Griess
reagent.
α1-ARs increase DNA synthesis in human coronary artery
ECs (Fig. 4)
Increased DNA synthesis in ECs is a marker for cellular
proliferation and angiogenesis. To test whether stimulation
of α1-ARs on human coronary ECs increases DNA
synthesis, we measured 3H-thymidine incorporation after
treatment with varying concentrations of NE (1 nM–
20 μM) in the presence of propranolol. NE increased 3H-
thymidine incorporation by a modest but significant extent
(maximum 1.3-fold, p=0.04 by ANOVA, N=3–5), with a
low EC50 (39 nM) (Fig. 4). Prazosin (0.2 μM) eliminated
stimulation by NE (data not shown), indicating that the
effect was mediated by α1-ARs. By comparison, 5% FBS
increased 3H-thymidine incorporation by 2.6-fold.
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Fig. 3 α1-AR stimulation activates eNOS in coronary ECs.
Cultured ECs were treated for 15–60 min (a) with EPI (2 μM) in
the presence of propranolol (1 μM), and phosphorylation of eNOS
Ser-1177 was assayed by immunoblot. Maximum activation was at
30 min (N=3, b)
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Discussion
This study provides the first characterization of α1-ARs in
human epicardial coronary ECs and identifies the α1B as
the predominant and functional α1-AR subtype. The α1B
subtype is present at relatively high density, and stimulation
of the α1B with modest doses of agonist activates ERK and
eNOS and increases DNA synthesis. These results raise the
possibility that the α1B-AR subtype might have a role in the
important adaptive processes mediated by coronary ECs.
We used qPCR and pharmacology to identify the α1B as
the predominant and functional α1-subtype, because α1-AR
antibodies are not specific forα1-ARs orα1-subtypes (Jensen
et al. 2009c; Pradidarcheep et al. 2009). By qPCR with
validated primers, human coronary ECs expressed >90%
α1B mRNA, with very little α1D, and no detectable α1A.
In functional experiments, NE and EPI stimulated phos-
phorylation of ERK-Thr202/Tyr204 and eNOS-Ser-1177,
and the nonselective α1-antagonist prazosin blocked stimu-
lation by 70%. The potent and selective α1A agonist
A61603 did not activate ERK, and the general α2-agonist
UK-14,304 had a minor effect. To distinguish the α1B from
the α1D, we used the α1D-selective antagonist, BMY-7378,
because there are no drugs sufficiently selective for the α1B.
BMY-7378 inhibited α1-stimulated ERK phosphorylation
with low affinity, not the high-affinity characteristic of the
α1D. Thus, these data identified the α1B-subtype as
functional in human epicardial coronary ECs.
The high level of the α1B in ECs points to an important
difference in α1-subtypes in human coronary ECs and
SMCs. Recently, we used mRNA and functional assays to
show that the α1D subtype is predominant and functional
in human coronary SMCs (Jensen et al. 2009b). The α1D is
also predominant when assayed by qPCR and radioligand
binding in intact human epicardial coronary arteries (Jensen
et al. 2009b). However, when binding was done on isolated
cells, as in the present study, the density of the α1B in ECs
was twice that of the α1D in SMCs (34 vs. 17 fmol/mg).
Thus, the much larger total mass of SMCs likely explains
the α1D predominance in intact coronaries, rather than a
higher density of α1-ARs on SMCs than on ECs. In fact, it
is notable that a minor population of the α1B is detectable
in intact human epicardial coronaries (less than 25%;
Jensen et al. 2009b).
As noted in the “Introduction,” α1-stimulation causes
minimal constriction of normal coronary arteries but leads to
markedly augmented vasoconstriction in coronary arteries
with disrupted endothelium. The α1D is predominant in
coronary SMCs (Jensen et al. 2009b); the α1D can cause
coronary constriction in the α1A and α1B double knockout
mouse; and coronary constriction is blunted in the single
α1D knockout mouse (Chalothorn et al. 2003; Turnbull et al.
2003). Therefore, it is interesting to speculate whether loss of
the coronary EC α1B might be responsible for α1-mediated
constriction through the α1D when the endothelium is
disrupted, as in atherosclerosis. The coronary EC α1B might
mediate counter-regulatory vasodilation by stimulating
eNOS, as shown here. The α1B might also have a role in
EC proliferation and angiogenesis, given the stimulation of
3H-thymidine uptake found here. More sophisticated studies
in knockout mice will be needed to test these hypotheses,
because the α1B and α1D are very difficult to distinguish by
pharmacology, especially in intact animals.
In summary, our present and past results indicate that the
α1-AR subtypes are expressed heterogeneously in the human
heart. The α1B is in human epicardial coronary ECs; the α1D
is in human epicardial coronary SMCs (Jensen et al. 2009b);
and the α1A and α1B are in human myocardium (Jensen et
al. 2009a). Drugs used for prostate disease and hypertension
that block all α1-subtypes nonselectively have adverse
cardiac effects in human clinical trials (Cohn 1993;
ALLHAT CRG 2000; ALLHAT 2003), and mouse knock-
outs show that loss of cardiac α1A and α1B signaling could
account for these adverse effects (O’Connell et al. 2003,
2006). The α1A subtype has a protective role in cardiac
myocytes (Huang et al. 2007; Chan et al. 2008), and the
α1B in epicardial coronary ECs might also have an adaptive
role. Potential risks of blocking the α1A and α1B might be
avoided with α1D-selective drugs, such as naftopidil, to
relax both prostate and coronary smooth muscle (Takei et al.
1999; Nishino et al. 2006; Kojima et al. 2009).
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